Inhibition of HIV replication in vitro by fusidic acid. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Inhibition of HIV replication in vitro by fusidic acid.

Lancet. 1987 Oct 10;2(8563):827-8. Unique Identifier : AIDSLINE MED/88012874
Faber V; Dalgleish AG; Newell A; Malkovsky M; University Hospital of Copenhagen, Denmark.

Abstract: A 58-year-old man with AIDS improved clinically after the introduction of fusidic acid, 500 mg three times a day orally, to his therapeutic regimen. Fusidic acid may have had a direct effect against HIV. Fusidic acid has anti-HIV activity in vitro at levels readily attainable in vivo. The drug does not appear to be a reverse transcriptase inhibitor and its mode of action against HIV is unknown. Fusidic acid can be given orally and has few side-effects. These results justify fuller evaluation of fusidic acid as therapy against AIDS and HIV infection.
Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Case Report Cytopathogenic Effect, Viral/DRUG EFFECTS Drug Therapy, Combination Fusidic Acid/*PHARMACOLOGY/THERAPEUTIC USE Human HIV/*DRUG EFFECTS Male Middle Age Reverse Transcriptase/ANTAGONISTS & INHIB Virus Replication/*DRUG EFFECTS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/drugtherapycasereportcytopathogeniceffect,viral/drugeffectsdrugtherapy,combinationfusidicacid/KWDpharmacology/therapeuticusehumanhiv/KWDdrugeffectsmalemiddleagereversetranscriptase/antagonists&inhibvirusreplication/KWDdrugeffectsjournalarticle
880130
M8810026

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .